Our previous studies showed that Tat-SP4 promoted endolysosomal degradation of EGFR and HER2, which are oncogenic drivers for non-small cell lung cancer (NSCLC) and HER2+ breast cancer subtype respectively [30]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.